Daix (France), Long Island City (New York, United States), February 15, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a biopharmaceutical company specializing in the clinical development of small molecules administered by oral route for the treatment of nonalcoholic steatohepatitis (NASH) and other diseases with an unmet medical need, today releases a portion of its preliminary unaudited financial results as of December 31, 2023 and for the fiscal year ending then. date, including cash, cash equivalents, and turnover. The Company also provides an update on its NATiV3 clinical study.
Frédéric Cren, Chairman, CEO and co-founder of Inventiva, said: “2023 was a rich year for the Company. We achieved several key clinical milestones in our lanifibranor program, including entering into a new partnership with Hepalys Pharma Inc. to develop and commercialize lanifibranor for the treatment of NASH in Japan and South Korea. During the year, we also increased our financial position by raising approximately €36 million and through the receipt of an upfront payment of $10 million under our exclusive licensing agreement with Hepalys Pharma, Inc. .. This allowed us to draw down the second tranche of 25 million euros in January 2024 as part of the 50 million euro loan granted by the EIB.